Harten Group

Search form

Due Diligence

When you are looking at a new opportunity - either from a company perspective or as an investor - you will need some help with the due diligence process.

Harten Group can provide the expertise to fill that gap, to analyse the prescribing data and enable you to make that important decision.

Are you a company looking to assess a new health product for in-licensing? Or needing to review a pharmaceutical product portfolio of a potential merger or acquisition partner? Maybe you would like to obtain key opinion leader views on your medical device as part of the process?

If you are a venture capitalist or life sciences business angel, you will want to evaluate the company you are considering purchasing or investing in. How sound is the regulatory strategy? Does it have potentially successful products in the pipeline? Is the pricing and reimbursement plan realistic? How much is the Risk Management Plan going to cost?

By drawing on our network of over 2000 life sciences consultants, Harten Group can access therapeutic specialists, many of whom are key opinion leaders in their own right or closely connected to major players in the field.

Working closely with you, we will match our resources to your needs, whether it's an individual physician with in-depth knowledge in a specific therapeutic area or a full due diligence team with medical, regulatory and commercial specialists.

Previous projects have included providing a large cross-functional team to evaluate a portfolio of products for acquisition to collating key opinion views across the top five EU markets, to complete the due diligence on the likely product positioning of a novel compound.

Call Dr Vernon Harten-Ash on +44 (0)1223 233777 for a confidential discussion.

We had the opportunity to buy a product range from a major pharmaceutical company and needed specialist help to evaluate the offering and assess its commercial worth across global markets. It was essential to move quickly and Harten Group was able to provide a team of consultants who really did hit the ground running to deliver the information we required on deadline

Managing Director, Top 2 UK Generics Company


Latest assignments

Phase I/II Physician

6 months, likely to extend

Medical Director / Clinical Science Director

6 months, likely to extend

Interim Medical Director

6 months, likely to extend

Recent projects & updates

A consultant has been helping a generics company headquartered in Ireland, currently branching into branded pharmaceuticals, with training and raising awareness of the Code to ensure local and UK compliance.

Harten Group consultant handles all regulatory requirements for compiling and submitting monthly safety updates for a global pharma company's antiviral during flu epidemic.

Read full details >>